Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years-Results of the POLAC Project.
Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years-Results of the POLAC Project.
复制标题
DOI：
10.3390/jcm10184176
复制
发表时间：
2021-09-15
影响因子：
3.9
通讯作者：
Marczyńska M
中科院分区：
文献类型：
--
作者：
Pokorska-Śpiewak M;Dobrzeniecka A;Aniszewska M;Marczyńska M
Background: Available real-world data on the efficacy and safety of ledipasvir/sofosbuvir (LDV/SOF) in pediatric patients are limited. In this prospective, open-label, single-center study, we aimed to present our real-life experience with a fixed dose of LDV/SOF (90/400 mg) for the treatment of chronic hepatitis C (CHC) genotypes 1 and 4 in children aged 12 to 17 years. Methods: We analyzed intention-to-treat (ITT) and per-protocol (PP) rates of sustained virological response (SVR), defined as undetectable HCV viral load at posttreatment week 12, in 37 participants treated with LDV/SOF according to the HCV genotype, baseline liver fibrosis, duration of treatment, and experience of the previous ineffective antiviral treatment. There were 32 patients infected with genotype 1 and 5 with genotype 4. Fourteen (38%) participants were treatment-experienced, two were coinfected with HIV, and three were cirrhotic. Two patients qualified for 24 weeks of therapy, and the remaining 35 received 12 weeks of LDV/SOF treatment. Results: The overall ITT SVR12 rate was 36/37 (97%). One patient was lost to follow-up after week 4 of therapy when his HCV RNA was undetectable. All 36 patients who completed the full protocol achieved SVR (36/36, 100%). PP analyses of SVR12 rates according to the HCV genotype, baseline liver fibrosis, duration of the treatment, and previous ineffective treatment were all 100%. A significant decrease in aminotransferase serum levels was observed in the subsequent weeks of the treatment and at SVR assessment compared to baseline. No serious adverse events were reported. Conclusions: The results of this study confirm previous observations of a suitable efficacy and safety profile of LDV/SOF for the treatment of CHC genotypes 1 and 4 in adolescents.
登录
查看更多内容
DOI：
10.1097/mpg.0000000000002449
发表时间：
2019-11-01
影响因子：
2.9
作者：
Serranti, Daniele;Dodi, Icilio;Indolfi, Giuseppe
通讯作者：
Indolfi, Giuseppe
影响因子：
3.2
作者：
Fouad, Hanan M.;Sabry, Magda A.;Aziz, Hossam Abdel
通讯作者：
Aziz, Hossam Abdel
影响因子：
35.7
作者：
Schmelzer, Jonathan;Dugan, Ellen;El Sayed, Mortal Hamdy
通讯作者：
El Sayed, Mortal Hamdy
DOI：
10.1097/mpg.0000000000001872
发表时间：
2018-03-01
影响因子：
2.9
作者：
Indolfi, Giuseppe;Hierro, Loreto;Fischler, Bjorn
通讯作者：
Fischler, Bjorn
影响因子：
5.7
作者：
Jaroszewicz, Jerzy;Pawlowska, Malgorzata;Flisiak, Robert
通讯作者：
Flisiak, Robert